- Home
- UPXI vs ADTX Comparison
UPXI vs ADTX Comparison
Compare UPXI & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- ADTX
- Stock Information
- Founded
- UPXI 2018
- ADTX 2017
- Country
- UPXI United States
- ADTX United States
- Employees
- UPXI N/A
- ADTX N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- UPXI Health Care
- ADTX Health Care
- Exchange
- UPXI Nasdaq
- ADTX Nasdaq
- Market Cap
- UPXI 4.6M
- ADTX 5.3M
- IPO Year
- UPXI 2021
- ADTX 2020
- Fundamental
- Price
- UPXI $2.92
- ADTX $0.09
- Analyst Decision
- UPXI Hold
- ADTX
- Analyst Count
- UPXI 1
- ADTX 0
- Target Price
- UPXI $25.00
- ADTX N/A
- AVG Volume (30 Days)
- UPXI 71.1K
- ADTX 150.6M
- Earning Date
- UPXI 02-14-2025
- ADTX 04-15-2025
- Dividend Yield
- UPXI N/A
- ADTX N/A
- EPS Growth
- UPXI N/A
- ADTX N/A
- EPS
- UPXI N/A
- ADTX N/A
- Revenue
- UPXI $18,625,089.00
- ADTX $212,107.00
- Revenue This Year
- UPXI $299.03
- ADTX $95.61
- Revenue Next Year
- UPXI N/A
- ADTX $1,584.79
- P/E Ratio
- UPXI N/A
- ADTX N/A
- Revenue Growth
- UPXI 4.75
- ADTX N/A
- 52 Week Low
- UPXI $2.17
- ADTX $0.07
- 52 Week High
- UPXI $15.91
- ADTX $218.00
- Technical
- Relative Strength Index (RSI)
- UPXI 34.56
- ADTX 36.78
- Support Level
- UPXI $3.35
- ADTX $0.07
- Resistance Level
- UPXI $4.50
- ADTX $0.16
- Average True Range (ATR)
- UPXI 0.36
- ADTX 0.02
- MACD
- UPXI -0.06
- ADTX 0.01
- Stochastic Oscillator
- UPXI 5.39
- ADTX 28.49
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products. It reaches consumers through its direct-to-consumer network, wholesale partnerships, and prominent third-party platforms like Amazon.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.